Biogen

BMO Capital Markets isn't calling the bottom on Biogen Inc (NASDAQ: BIIB) despite the risk to its MS franchise and Spinraza getting priced in. With Biogen's MS franchise thesis playing out, BMO upgraded shares of the company from Market Perform to Outperform and lowered its price target...

This weekend's Barron's looks at the prospects for a leading tire manufacturer. The prospects for a healthcare giant and a dialysis pioneer are also examined. Other featured articles offer picks from a London hedge fund conference and a look at the Dow Jones Industrial Average as...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out among the few that bucked the trend in those two weeks. Shares of one of those two stocks slumped more than 22 percent during the period. Short sellers shied away from many of...

Short interest in many of the leading biotech stocks shrank in the most recent period. Two stocks in particular stood out as leaders of that trend in those two weeks. Shares of one of those two stocks rose while the other slumped during the period. Short sellers moved on only a few of the leading...

A special report in this weekend's Barron's offers the results of the latest exclusive annual survey of companies with superior operating performance. See which drug wholesaler soared to the top of list for 2016. Other featured articles discuss the impending defeat of ISIS and the...

Short interest in many leading biotech stocks declined in the most recent period. Bucking that trend is a biotech company that soon will be acquired by an overseas peer. Short sellers retreated most sharply from a biotech that some analysts now see as a value stock. Between the March 31 and April...

Short interest moves in leading biotech stocks were mixed in the most recent period. However, Illumina, Inc. (NASDAQ: ILMN) and Baxalta Inc (NYSE: BXLT) saw sharp increases in their short interest in late November. Short sellers appeared to lose interest in Juno Lighting LLC (NASDAQ: JUNO) late in...

Insiders activity is beginning to rise, following third-quarter reports. Recent insider buying includes the two beaten-down biotechs. Strong insider buying is often considered a positive sign for investors. As investors start to look ahead to the end of the year, and windows for...

Short-sellers continued to be selective in the leading biotech stocks in the most recent period. Biogen and Medivation saw sharp drops in their short interest in early October. The number of Amgen shares short surged during that time. In the wake of ongoing market volatility and...

Short interest changes in biotech stocks were mixed during the most recent period. Baxalta Inc (NYSE: BXLT) and Juno Therapeutics Inc (NASDAQ: JUNO) saw short interest surges in late September. Short interest in Medivation Inc (NASDAQ: MDVN) plunged during that time. With the ongoing market...

Between the July 31 and August 14 settlement dates, the number of shares short in the leading biotech and emerging pharmaceutical stocks was mixed. Short sellers were especially drawn to Biogen Inc (NASDAQ: BIIB), Gilead Sciences, Inc. (NASDAQ: GILD) and Vertex Pharmaceuticals Incorporated (...

In a note to clients on Friday, Evercore ISI analyst Mark Schoenebaum commented that investors were expecting Biogen Inc (NASDAQ: BIIB) to report a "weak quarter" but its print actually came in "probably even worse" than expected. Biogen earned $4.22 per share in the second quarter, beating the $4....